2023 World Conference on Lung Cancer (Posters)-EP12.01. Liquid Biopsy Reduce Time to Treatment for Patients with EGFR mutated Advanced Nonsquamous Non-small Cell Lung Cancer : A Mexican Unit Experience

EP12.01. Liquid Biopsy Reduce Time to Treatment for Patients with EGFR mutated Advanced Nonsquamous Non-small Cell Lung Cancer : A Mexican Unit Experience - PDF(Abstract)

Back to course

Pdf Summary

Liquid biopsy is a minimally invasive diagnostic method that involves analyzing circulating tumor DNA (ctDNA) and other biomarkers in the blood. It can detect genetic alterations in tumors, such as EGFR mutations, without the need for a tissue biopsy. Traditionally, patients with advanced non-small cell lung cancer (NSCLC) have to undergo a tissue biopsy to determine the presence of EGFR mutations, which can take days or weeks for results to be available. This delay in diagnosis can impact patient outcomes as EGFR-mutated NSCLC is sensitive to targeted therapies. Liquid biopsy provides quicker results, sometimes within 24 hours, allowing patients to receive treatment sooner.<br /><br />The aim of the study was to describe the use of liquid biopsy for EGFR detection in a Thoracic Cancer Unit in Mexico. A total of 100 patients with advanced NSCLC were analyzed from January 2018 to December 2021. Digital next-generation sequencing was performed on their plasma to analyze EGFR mutations. Tissue testing was also done for 95 patients, and the data included test timing, time to treatment, stage, gender, and age.<br /><br />The results showed that 22% of patients had a positive plasma EGFR mutation, with most mutations occurring in exon 19. The median test timing was shorter for plasma compared to tissue PCR, and this led to EGFR inhibitor use in 91% of positive patients. The concordance between plasma and tissue evaluation was 90%.<br /><br />In conclusion, liquid biopsy is a valuable tool for diagnosing and monitoring EGFR-mutated advanced non-squamous NSCLC. It enables patients to receive timely and effective treatment, potentially improving their outcomes and contributing to better disease management.

Asset Subtitle

Saul Campos-Gomez

Meta Tag

Speaker Saul Campos-Gomez

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Liquid biopsy

minimally invasive

diagnostic method

circulating tumor DNA

ctDNA

biomarkers

genetic alterations

EGFR mutations

non-small cell lung cancer

NSCLC